Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK5864399 · 1 trial · 1 indication
cORR is defined as the proportion of participants who have achieved a Best of response (BOR) of Complete Response (CR) or Partial Response (PR) as assessed by the Investigator and confirmed by repeat assessments at least 4 weeks after the initial response is documented, according to Response Evaluation Criteria in Solid Tumours (RECIST) version (v) 1.1.
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose Escalation | EXPERIMENTAL | - |
| Part 2: Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GSK5864399 | DRUG | GSK5864399 will be administered |
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Is at least 18 years of age or the legal age of consent. * Has histologically confirmed unresectable metastatic disease of either: * colorectal cancer that has progressed thr...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GSK5864399 is an investigational small molecule being studied for the treatment of solid tumours. It is in Phase 1/2 clinical development and is not yet available as a marketed therapy. The program is being run by GSK plc.
GSK5864399 is being developed by GSK plc, which trades under the ticker GSK. The company is sponsoring the clinical program evaluating the compound in participants with solid tumours.
GSK5864399 is in Phase 1/2 clinical development. It is an investigational agent and has not completed the clinical testing required for regulatory approval. The single registered trial is currently listed as not yet recruiting.
GSK5864399 is being evaluated in trial NCT07947134, titled A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours. The Phase 1/Phase 2 trial is controlled, randomized, and plans to enroll 155 participants aged 18 years and older.
Trial NCT07947134 is designed to test GSK5864399 both as a single agent and in combination with other anti-cancer agents in participants with solid tumours. The study is randomized and controlled, with an planned enrollment of 155 participants.